* Aprea Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Aprea Therapeutics Inc is for a loss of 78 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Aprea Therapeutics Inc is $16.00, above its last closing price of $5.50.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.77 -0.92 Missed -19
Sep. 30 2023 -1.16 -1.16 -0.86 Beat 26.1
Jun. 30 2023 -1.42 -1.42 -0.87 Beat 38.9
Mar. 31 2023 -1.52 -1.50 -1.34 Beat 11
Dec. -4.04 -3.08 -0.92 Beat 70.1
31 2022
Sep. 30 2022 -9.20 -5.50 -2.40 Beat 56.4
Jun. 30 2022 -7.00 -7.50 -19.60 Missed -161.3
Jan. 1 0001 -7.60 -7.60 -7.20 Beat 5.3
This summary was machine generated May 10 at 11:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments